Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

CD4 T cells require ICOS-mediated PI3K signaling to increase T-Bet expression in the setting of anti-CTLA-4 therapy.

Chen H, Fu T, Suh WK, Tsavachidou D, Wen S, Gao J, Ng Tang D, He Q, Sun J, Sharma P.

Cancer Immunol Res. 2014 Feb;2(2):167-76. doi: 10.1158/2326-6066.CIR-13-0155. Epub 2013 Nov 19.

2.

An efficient procedure for protein extraction from formalin-fixed, paraffin-embedded tissues for reverse phase protein arrays.

Guo H, Liu W, Ju Z, Tamboli P, Jonasch E, Mills GB, Lu Y, Hennessy BT, Tsavachidou D.

Proteome Sci. 2012 Sep 24;10(1):56. doi: 10.1186/1477-5956-10-56.

3.

Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone.

Efstathiou E, Titus M, Tsavachidou D, Tzelepi V, Wen S, Hoang A, Molina A, Chieffo N, Smith LA, Karlou M, Troncoso P, Logothetis CJ.

J Clin Oncol. 2012 Feb 20;30(6):637-43. doi: 10.1200/JCO.2010.33.7675. Epub 2011 Dec 19.

4.

Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models.

Cheong JH, Park ES, Liang J, Dennison JB, Tsavachidou D, Nguyen-Charles C, Wa Cheng K, Hall H, Zhang D, Lu Y, Ravoori M, Kundra V, Ajani J, Lee JS, Ki Hong W, Mills GB.

Mol Cancer Ther. 2011 Dec;10(12):2350-62. doi: 10.1158/1535-7163.MCT-11-0497. Epub 2011 Oct 12.

5.

Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer.

Tsavachidou D, McDonnell TJ, Wen S, Wang X, Vakar-Lopez F, Pisters LL, Pettaway CA, Wood CG, Do KA, Thall PF, Stephens C, Efstathiou E, Taylor R, Menter DG, Troncoso P, Lippman SM, Logothetis CJ, Kim J.

J Natl Cancer Inst. 2009 Mar 4;101(5):306-20. doi: 10.1093/jnci/djn512. Epub 2009 Feb 24.

6.

Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma.

Kim J, Jonasch E, Alexander A, Short JD, Cai S, Wen S, Tsavachidou D, Tamboli P, Czerniak BA, Do KA, Wu KJ, Marlow LA, Wood CG, Copland JA, Walker CL.

Clin Cancer Res. 2009 Jan 1;15(1):81-90. doi: 10.1158/1078-0432.CCR-08-0170.

7.

SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant.

Tsavachidou D, Coleman ML, Athanasiadis G, Li S, Licht JD, Olson MF, Weber BL.

Cancer Res. 2004 Aug 15;64(16):5556-9.

8.

Modeling and simulation of pathways in menopause.

Tsavachidou D, Liebman MN.

J Am Med Inform Assoc. 2002 Sep-Oct;9(5):461-71.

Supplemental Content

Loading ...
Support Center